1Y Target$24.07Near-term target
5Y Target$33.71Compound horizon
10Y Target$49.55Long-dated conviction
FCF$213mTTM · 03/26CFCF $213m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+9.3%TTM YoYBRevenue +9.3% — at or above S&P median · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.88totalBD/E 0.88 — at market average, manageable · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E15.9xB+P/E 15.9 — at or below S&P median, reasonable
PEG1.71proxyC+PEG 1.71 — modest premium; above fair value · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $3.3b. Down 43% from 52-week high of $36.80 — deep drawdown territory.
Moat
ROE 15% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Down 43% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Net margin 3.6% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $24.07 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $33.71 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $49.55 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.